keyword
MENU ▼
Read by QxMD icon Read
search

Indolent lymphoma

keyword
https://www.readbyqxmd.com/read/28544534/time-to-event-analysis-of-polatuzumab-vedotin-induced-peripheral-neuropathy-to-assist-in-the-comparison-of-clinical-dosing-regimens
#1
D Lu, W R Gillespie, S Girish, P Agarwal, C Li, J Hirata, Y-W Chu, M Kagedal, L Leon, V Maiya, J Y Jin
Polatuzumab vedotin, an antibody-drug conjugate containing monomethyl auristatin E, was associated with an incidence of grade ≥2 peripheral neuropathy (PN) of 55-72% in patients with indolent non-Hodgkin lymphoma in a phase II study, when dosed 1.8-2.4 mg/kg every 3 weeks until progression or for a maximum of 17 cycles. To quantify the correlation of conjugate exposure and treatment duration with PN risk, a time-to-event model was developed using data from phase I and II studies. The model suggested that PN risk increased with conjugate exposure and treatment cycles, and a trend for increased risk with body weight and albumin concentration...
May 23, 2017: CPT: Pharmacometrics & Systems Pharmacology
https://www.readbyqxmd.com/read/28534374/rituximab-in-the-therapy-of-stage-iii-and-iv-follicular-lymphoma-results-of-the-reflect-1-study-of-the-serbian-lymphoma-group
#2
Stevan Popovic, Darjana Jovanovic, Biljana Mihaljevic, Nebojsa Andjelkovic, Goran Marjanovic, Dragomir Marisavljevic, Nada Vlaisavljevic, Lazar Popovic, Svetlana Salma, Danijela Agic, Rajko Milosevic, Mihajlo Smiljanic, Snezana Sretenović, Predrag Djurdjević, Olivera Markovic, Jelena Hajder, Nenad Govedarovic
PURPOSE: Follicular lymphoma (FL) is an indolent lymphoma that responds well to rituximab+chemotherapy. We evaluated the prognosis and efficacy of immunochemotherapy in patients with previously untreated, advanced FL. METHODS: REFLECT 1 is a multicentre, prospective study of 99 patients with previously untreated FL stage III-IV. All patients were treated with rituximab+chemotherapy x 6 cycles, plus 2 cycles of rituximab monotherapy. Clinical assessment was performed at baseline, after completion of the first 6 cycles of therapy and every 3 months from the end of immunochemotherapy to the end of the study period...
March 2017: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://www.readbyqxmd.com/read/28533834/-splenic-marginal-zone-lymphoma
#3
Sinaa Mohamed
Splenic marginal zone lymphoma (SMZL) is a rare B-cell lymphoma, well defined according to the 2016 WHO classification of tumors of the hematopoietic tissue, which can raise diagnostic problems. We report the case of a 72-year old patient, hospitalised for exploration of a massive splenomegaly confirmed by computed tomography (CT). Laboratory tests were normal. The patient underwent splenectomy. Microscopic examination of the surgical specimen showed widespread lymphomatous proliferation in small cells associated with CD20 marker...
2017: Pan African Medical Journal
https://www.readbyqxmd.com/read/28531181/weekly-versus-biweekly-bortezomib-given-in-patients-with-indolent-non-hodgkin-lymphoma-a-meta-analysis
#4
Ting Yuan, Feng Zhang, Qing-Min Yao, Yan-Xia Liu, Xiao-Juan Zhu, Xin Wang
BACKGROUND: Bortezomib is recently studied as a novel agent in indolent lymphoma. The optimal schedule of bortezomib used in indolent lymphoma is still uncertain. METHODS: We did a systematic review and meta-analysis of the clinical trials comparing the efficacy and toxicity of the weekly and biweekly schedules of bortezomib in patients with indolent lymphoma. We searched Pubmed, Cochrane Library and Emabase from inception to July 29, 2016. The primary outcome was the overall response rate including the complete response rate and the partial response rate...
2017: PloS One
https://www.readbyqxmd.com/read/28523163/a-single-center-experience-rituximab-plus-cladribine-is-an-effective-and-safe-first-line-therapy-for-unresectable-bronchial-associated-lymphoid-tissue-lymphoma
#5
Zheng Wei, Jing Li, Zhixiang Cheng, Ling Yuan, Peng Liu
BACKGROUND: Bronchial-associated lymphoid tissue (BALT) lymphoma is a relatively rare form of B-cell non-Hodgkin lymphoma (B-NHL). To date, the standard systemic treatment for this disease is still under debate, and few data are accessible for newly diagnosed unresectable BALT lymphoma presented with advanced disease. The combination of rituximab (R) and cladribine (2-CdA) has shown some activity in indolent B-NHL, but its usage has not been tested in disseminated BALT lymphoma so far...
April 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/28516439/reassessment-of-anti-cd20-therapy-in-lymphoid-malignancies-impact-limitations-and-new-directions
#6
REVIEW
Patrick M Reagan, Jonathan W Friedberg
The addition of anti-CD20 monoclonal antibodies to the treatment of B-cell malignancies has dramatically affected the field as well as the lives of patients. Rituximab in particular has been combined safely with conventional chemotherapy and has resulted in improved overall survival in major histologic subtypes of B-cell lymphoma and chronic lymphocytic leukemia. It is incorporated into the standard initial treatment of nearly all of these diseases. Novel anti-CD20 antibodies are currently under development...
May 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28515095/a-prognostic-index-for-chronic-and-smoldering-type-adult-t-cell-leukemia-lymphoma
#7
Hiroo Katsuya, Mototsugu Shimokawa, Kenji Ishitsuka, Kazuhiro Kawai, Masahiro Amano, Atae Utsunomiya, Ryosuke Hino, Shuichi Hanada, Tatsuro Jo, Kunihiro Tsukasaki, Yukiyoshi Moriuchi, Eisaburo Sueoka, Shinichiro Yoshida, Hitoshi Suzushima, Masaharu Miyahara, Kiyoshi Yamashita, Tetsuya Eto, Junji Suzumiya, Kazuo Tamura
Adult T-cell leukemia-lymphoma (ATL) has been divided into 4 clinical subtypes: acute, lymphoma, chronic, and smoldering. The aim of this study is to develop a novel prognostic index (PI) for chronic and smoldering ATL. We conducted a nationwide retrospective survey on ATL patients, and 248 fully eligible individuals were used in this analysis. In the univariate analysis, gender, performance status, log10[soluble interleukin-2 receptor (sIL-2R)], neutrophils count, and lymphadenopathy showed P values less than ...
May 17, 2017: Blood
https://www.readbyqxmd.com/read/28505007/al-amyloidoma-of-the-skin-subcutis-cutaneous-amyloidosis-plasma-cell-dyscrasia-or-a-manifestation-of-primary-cutaneous-marginal-zone-lymphoma
#8
Noreen M Walsh, Ian Marie Lano, Peter Green, Christopher Gallant, Sylvia Pasternak, Thai Yen Ly, Luis Requena, Heinz Kutzner, Andreas Chott, Lorenzo Cerroni
It is unclear whether AL amyloidoma of the skin/subcutis represents a distinct entity, an indolent precursor of systemic amyloidosis, or a manifestation of cutaneous marginal zone lymphoma (cMZL). We collected 10 cases of cutaneous AL amyloidoma in order to better characterize the clinicopathologic features of this elusive entity (M:F=4:6; median age: 62.5 y, range: 31 to 82 y). Nine patients had a solitary nodule or plaque on the lower extremity (n=7), upper extremity (n=1), or chin (n=1). One patient had an AL amyloidoma on the right thigh and a second lesion on the right arm showing histopathologic features of cMZL without amyloid deposits...
May 12, 2017: American Journal of Surgical Pathology
https://www.readbyqxmd.com/read/28498285/c-myc-and-its-main-ubiquitin-ligase-fbxw7-influence-cell-proliferation-and-prognosis-in-adult-t-cell-leukemia-lymphoma
#9
Yasuhito Mihashi, Mikio Mizoguchi, Yasushi Takamatsu, Kenji Ishitsuka, Hiromi Iwasaki, Monji Koga, Kazunori Urabe, Seiya Momosaki, Toshifumi Sakata, Fumiaki Kiyomi, Morishige Takeshita
Smoldering-type and chronic-type adult T-cell leukemia/lymphomas (ATLL) patients have relatively indolent clinical courses, but often progress into aggressive lymphoma-type and acute-type disease. We examined the roles of transcription factor C-MYC and its ubiquitin ligase FBXW7 in tumor tissues from 137 patients with ATLL. Immunohistochemical tests showed ≥50% of lymphoma cells in 78.7% (48/61) of lymphoma-type, and 64.9% (24/37) of acute-type samples expressed C-MYC, significantly higher than was seen in smoldering-type (3...
May 11, 2017: American Journal of Surgical Pathology
https://www.readbyqxmd.com/read/28497585/disseminated-cd8-positive-cd30-positive-cutaneous-lymphoproliferative-eruption-with-overlapping-features-of-mycosis-fungoides-and-primary-cutaneous-anaplastic-large-cell-lymphoma-following-remote-solitary-lesional-presentation
#10
Jonathan J Davick, Krishna Aj Mutgi, Karolyn A Wanat, Brian K Link, Vincent Liu
CD8-positive, CD30-positive cutaneous lymphoproliferative disorders comprise a rare subset of T-cell lymphoproliferative conditions, including variants of primary cutaneous anaplastic large cell lymphoma, mycosis fungoides, lymphomatoid papulosis type D, cutaneous gamma-delta T-cell lymphoma, and cutaneous peripheral T-cell lymphoma. These entities share overlapping clinical, histopathologic, and immunophenotypic features, presenting both a clinical and pathological diagnostic challenge. Presented here is a 73-year-old man with a disseminated, indolent CD30+, CD8+ cutaneous lymphoproliferative disorder with overlapping clinical and histopathological features of both mycosis fungoides and primary cutaneous anaplastic large cell lymphoma, as well as features of lymphomatoid papulosis...
May 12, 2017: Journal of Cutaneous Pathology
https://www.readbyqxmd.com/read/28494924/loss-of-cd45-cell-surface-expression-in-canine-t-zone-lymphoma-results-from-reduced-gene-expression
#11
V Martini, M Cozzi, A Aricò, G Dalla Rovere, A Poggi, F Albonico, M Mortarino, E Ciusani, L Aresu, S Comazzi
Canine T-zone lymphoma (TZL) is a peculiar lymphoma subtype characterized by an indolent clinical course and aberrant CD45-negative phenotype, commonly recognized by flow cytometry (FC). Recent studies have described clinical presentation and behavior, but to date the mechanisms behind the loss of CD45 protein expression have never been investigated. The aims of this study were: 1) to confirm the absence of CD45 in canine TZL via the concomitant use of FC and immunohistochemistry with two different sources of antibody; and 2) to investigate the amount of CD45 transcript and the presence of CD45 gene in the neoplastic cells of dogs affected by TZL...
May 2017: Veterinary Immunology and Immunopathology
https://www.readbyqxmd.com/read/28494631/learning-from-the-failures-of-drug-discovery-in-b-cell-non-hodgkin-lymphomas-and-perspectives-for-the-future-chronic-lymphocytic-leukemia-and-diffuse-large-b-cell-lymphoma-as-two-ends-of-a-spectrum-in-drug-development
#12
Boris Kubuschok, Martin Trepel
Despite substantial recent advances, there is still an unmet need for better therapies in B-cell non Hodgkin lymphomas (B-NHL), especially in relapsed or refractory disease. Many novel targeted drugs have been developed based on a better molecular understanding of B-NHL. Areas covered: This article focuses on chronic lymphocytic leukemia (CLL) as a representative for indolent lymphomas and paradigmatic for the tremendous progress in treating B-NHL on the one hand and diffuse large B-cell lymphoma (DLBCL) as a representative for aggressive lymphomas and paradigmatic for many unsolved problems in lymphoma treatment on the other hand...
May 12, 2017: Expert Opinion on Drug Discovery
https://www.readbyqxmd.com/read/28491852/a-case-of-recurrent-hematuria-in-primary-prostatic-low-grade-mucosa-associated-lymphoid-tissue
#13
Saeed Hashemzadeh, Farid Farrokhi, Amir Hozhabrossadaty, Kamran Ghafarzadegan, Hami Ashraf
BACKGROUND: Primary mucosa-associated lymphoid tissue (MALT) lymphoma is a rare malignancy. We found only 8 cases of MALT lymphoma in literature. CASE PRESENTATION: We report here another case of primary prostatic MALT lymphoma which is presented by hematuria and diagnosed primarily as BPH. Immunohistochemistry studies demonstrate the diagnosis and MALT lymphoma. Six months after starting the treatment the patient was alive and well. CONCLUSIONS: Prostatic MALTomas are mainly presented with urinary obstruction or hematuria and have an indolent growth with a good prognosis...
March 2017: Journal of Nephropathology
https://www.readbyqxmd.com/read/28483372/role-of-plasma-cells-in-waldenstr%C3%A3-m-macroglobulinaemia
#14
REVIEW
Ali El-Ayoubi, James Q Wang, Nadine Hein, Dipti Talaulikar
Waldenström macroglobulinaemia (WM) is an indolent mature B cell lymphoma characterised by an infiltrate of heterogeneous B cells and hypersecretion of IgM. There are two distinct cellular populations that can be distinguished on morphology and immunophenotyping within the bone marrow. The predominant lymphoplasmacytic compartment arises at an earlier stage in ontogeny, and is responsible for the cytopenias noted during the symptomatic phase of the disease. This population is ably targeted by B cell immunodepletion...
May 5, 2017: Pathology
https://www.readbyqxmd.com/read/28480766/follicular-lymphomas-and-their-transformation-past-and-current-research
#15
Miriam Mendez, Maria Torrente, Mariano Provencio
Follicular lymphoma (FL) is the second most common type of non-Hodgkin lymphoma (NHL). Histological transformation (HT) refers to the evolution of a clinically indolent NHL to a clinically aggressive one, defined as those lymphomas in which survival is limited to a few months when untreated. Areas covered: HT is associated with rapid progression of lymphadenopathy, infiltration of extranodal sites, development of systemic symptoms, and elevated serum level of lactate dehydrogenase (LDH). It is frequently related to a poor prognosis, and the median survival after transformation is less than 2 years...
May 16, 2017: Expert Review of Hematology
https://www.readbyqxmd.com/read/28469834/ibrutinib-associated-skin-toxicity-a-case-of-maculopapular-rash-in-a-79-year-old-caucasian-male-patient-with-relapsed-waldenstrom-s-macroglobulinemia-and-review-of-the-literature
#16
Anders Bisgaard Jensen, Birgitte Stausbøl-Grøn, Rikke Riber-Hansen, Francesco d'Amore
Waldenstrom's macroglobulinamia (WM) is a rare malignant lymphoproliferative disorder, characterized by monoclonal IgM paraproteinemia and neoplastic proliferation of malignant lymphoplasmacytoid cells in the bone marrow. Traditionally, WM has been treated with modalities similar to those used in the management of other indolent lymphomas. Just recently, based on impressive clinical trial results in heavily pretreated WM patients, a new Bruton Tyrosine Kinase-inhibitor, Ibrutinib, has been approved for the treatment of this disorder...
March 13, 2017: Dermatology Reports
https://www.readbyqxmd.com/read/28466437/role-of-sox11-and-genetic-events-cooperating-with-cyclin-d1-in-mantle-cell-lymphoma
#17
REVIEW
Sílvia Beà, Virginia Amador
Mantle cell lymphoma (MCL) is an aggressive lymphoid neoplasm, incurable with current therapies. The t(11;14)(q13;q32) involving cyclin D1 is considered the first oncogenic hit found in virtually all MCLs. However, additional secondary genomic alterations are essential for complete transformation. MCLs are genetically very unstable with several genetic alterations associated with its high proliferative behavior involving several oncogenic pathways. Furthermore, SOX11 is overexpressed in the majority of conventional MCLs (cMCL), including cyclin D1-negative cases, but absent in non-nodal leukemic MCL with indolent clinical behavior (nnMCL)...
June 2017: Current Oncology Reports
https://www.readbyqxmd.com/read/28457544/treatment-outcomes-in-patients-with-extranodal-marginal-zone-b-cell-lymphoma-of-the-lung
#18
Hyun Lee, Bumhee Yang, Boda Nam, Byeong-Ho Jeong, Sumin Shin, Jae Il Zo, Young Mog Shim, O Jung Kwon, Kyung Soo Lee, Hojoong Kim
OBJECTIVES: To evaluate clinical presentations, treatment modalities, and outcomes of pulmonary mucosa-associated lymphoid tissue (MALT) lymphoma by stage strata. METHODS: We retrospectively reviewed 51 patients diagnosed with pulmonary MALT lymphoma between January 2003 and December 2015. To compare treatment modalities and outcomes, we stratified the patients into low-stage (IE/IIE) and high-stage (IIIE/IVE) groups using modified Ann Arbor staging. Progression-free survival was estimated using Kaplan-Meier curves, and differences were compared using the log-rank test...
March 21, 2017: Journal of Thoracic and Cardiovascular Surgery
https://www.readbyqxmd.com/read/28456850/influence-of-body-mass-index-on-survival-in-indolent-and-mantle-cell-lymphomas-analysis-of-the-stil-nhl1-trial
#19
Lukas Weiss, Thomas Melchardt, Alexander Egle, Georg Hopfinger, Hubert Hackl, Richard Greil, Juergen Barth, Mathias Rummel
Obesity is a well-known risk factor for the development of cancer, but its influence on the course of disease is still controversial. We investigated the influence of body mass index (BMI) on overall survival (OS) in 502 patients with indolent non-Hodgkin's lymphoma or mantle cell lymphoma in a subgroup analysis of the StiL (Study Group Indolent Lymphomas) NHL1 trial. We defined a cut-off of 22.55 kg/m(2) by ROC calculation and Youden Index analysis and stratified patients into "low BMI" and "high BMI". Five-year OS was significantly longer in the high BMI group (82...
April 30, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/28446319/-progress-on-treatment-of-splenic-marginal-zone-lymphoma-review
#20
Ling Wu, Chen Tian, Yi-Zhuo Zhang
Splenic marginal zone lymphoma (SMZL) is an uncommon indolent B-cell non-Hodgkin's lymphoma. The clinical features of SMZL are splenomegaly, lymphocytosis and cytopenia in peripheral blood. Immunopheno-typically, the neoplastic cells are typically positive for CD45, CD20, CD79a, PAX5, IgD, BCL-2. The previous common used treatment is splenectomy and chemotherapy. Nowadays, rituximab-based chemotherapy regimens has improved the curative effect dramaticlly. IFN-α with or without ribavirin can be used to treat the patients with HCV infection...
April 2017: Zhongguo Shi Yan Xue Ye Xue za Zhi
keyword
keyword
99818
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"